Skip to main content
Premium Trial:

Request an Annual Quote

NINDS Awards Coriell Institute $7.7M to Support Biorepository

NEW YORK – The US National Institute of Neurological Disorders and Stroke (NINDS) has awarded Coriell Institute for Medical Research $7.7 million for ongoing support of its biorepository.

Under the terms of the five-year contract, Coriell will continue to support the NINDS Human Genetics Research Center. Camden, New Jersey-based Coriell has been the contractor for the NINDS center since its establishment in 2002.

NINDS' biorepository includes samples from subjects with various diseases, including cerebrovascular disease, dystonia, epilepsy, motor neuron disease, parkinsonism, and Tourette syndrome. It also collects demographic, clinical, and other genetic data, which it makes available to researchers globally.

According to Coriell, the new money will support sample processing as well as storage and distribution at the center, in addition to the expansion of resource sub-collections, such as those focused on cerebrovascular disease and dystonia.

The contract will also support work to link samples to genomic data stored in dbGAP, the database of National Institutes of Health Genotypes and Phenotypes.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.